{
    "2021-09-02": [
        [
            {
                "time": "",
                "original_text": "康泰生物：腺病毒载体新冠疫苗已完成临床前研究并提交了临床试验申请",
                "features": {
                    "keywords": [
                        "腺病毒载体",
                        "新冠疫苗",
                        "临床前研究",
                        "临床试验申请"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": ""
                }
            },
            {
                "time": "",
                "original_text": "康泰生物：13价肺炎球菌结合疫苗申请的药品注册批件在审批中",
                "features": {
                    "keywords": [
                        "13价肺炎球菌结合疫苗",
                        "药品注册",
                        "审批中"
                    ],
                    "sentiment_score": 0.85,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": ""
                }
            },
            {
                "time": "",
                "original_text": "康泰生物：实控人杜伟民质押139万股及解押400万股",
                "features": {
                    "keywords": [
                        "实控人",
                        "杜伟民",
                        "质押",
                        "解押"
                    ],
                    "sentiment_score": -0.2,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "",
                "original_text": "医药行业2021年9月投资策略暨中报总结：政策预期基线变化中消化估值",
                "features": {
                    "keywords": [
                        "医药行业",
                        "投资策略",
                        "政策预期",
                        "估值"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "true",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "",
                "original_text": "天风证券维持康泰生物买入评级：乙肝疫苗恢复生产，新冠疫苗带来业绩弹性",
                "features": {
                    "keywords": [
                        "天风证券",
                        "买入评级",
                        "乙肝疫苗",
                        "新冠疫苗",
                        "业绩弹性"
                    ],
                    "sentiment_score": 0.95,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": ""
                }
            }
        ]
    ]
}